Healthcare - Biotechnology - NASDAQ - US
$ 6.96
-12.1 %
$ 216 M
Market Cap
-2.56
P/E
INCOME STATEMENT
0
REVENUE
-67.2 M
OPERATING INCOME
-60.4 M
NET INCOME
EFFICIENCY
Earnings Waterfall
Acrivon Therapeutics, Inc. Common Stock
| Revenue | 0 |
| Cost Of Revenue | 536 K |
| Gross Profit | -536 K |
| Operating Expenses | 66.7 M |
| Operating Income | -67.2 M |
| Other Expenses | -6.85 M |
| Net Income | -60.4 M |
Income Statement
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | |
|---|---|---|---|---|
| REVENUE | ||||
| Revenue | 0 | 0 | 0 | 0 |
| GROSS PROFIT | ||||
| Cost Of Revenue | 0.5 | 1.1 | 0.8 | 13 K |
| Gross Profit | (0.5) | (1.1) | (0.8) | 13 K |
| OPERATING INCOME | ||||
| Operating Expenses | 66.7 | 32.7 | 16.2 | 3.2 |
| Selling, General and Administrative Expenses | 21.2 | 8.7 | 2.5 | 1.3 |
| Research and Development Expenses | 45.5 | 23.9 | 13.7 | 1.9 |
| Operating Income | (67.2) | (32.7) | (16.2) | (3.2) |
| PRE-TAX INCOME | ||||
| Interest Income Expense | 0 | (1.5) | 0 | 0 |
| Total Other Income | 6.8 | 1.5 | 59 K | (2.1) |
| Pre-Tax Income | (60.4) | (31.2) | (16.2) | (5.3) |
| NET INCOME | ||||
| Tax Provision | 0 | (1.5) | (0.2) | (0.2) |
| Net Income | (60.4) | (29.7) | (16.2) | (5.3) |
| EPS | 2.74 | 1.35 | 0.78 | 0.25 |